Grown Rogue International (GRUSF) Non-Current Assets (2011 - 2026)
Grown Rogue International (GRUSF) posted quarterly Non-Current Assets of $41.0 million for Q1 2026, up 90.58% year-over-year from $21.5 million in Q1 2025, and up 2334.24% quarter-over-quarter from $1.7 million in Q4 2025.
Grown Rogue International (GRUSF) Non-Current Assets (2011 - 2026) Analysis & Trends
Grown Rogue International's Non-Current Assets history runs 16 years deep, the most recent figure standing at $41.0 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 90.58% year-over-year to $41.0 million; the TTM figure through Mar 2026 stood at $72165.3 billion (up 100827772.62% YoY), while the FY2025 annual figure was $1.7 million, up 9.48% from the prior year.
- Non-Current Assets for Q1 2026 stood at $41.0 million, up from $1.7 million in the prior quarter.
- The five-year high for Non-Current Assets was $48078.5 billion in Q2 2025, with the low at $1.5 million in Q4 2024.
- The 5-year median for Non-Current Assets is $13.9 million (2023), against an average of $5154.7 billion.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets slumped 85.05% in 2024, then soared 320009577.44% in 2025.
- Grown Rogue International's Non-Current Assets stood at $6.4 million in 2022, then soared by 61.48% to $10.3 million in 2023, then plunged by 85.05% to $1.5 million in 2024, then advanced by 9.48% to $1.7 million in 2025, then jumped by 2334.24% to $41.0 million in 2026.
- Business Quant data shows GRUSF's Non-Current Assets at $41.0 million in Q1 2026, $1.7 million in Q4 2025, and $24086.7 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 2.96 Bn |
| 10 | Grown Rogue International | 113.47 Mn | 101.93 Mn | 5.37 Mn | 42.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.47 Mn |
| Mar 31, 2026 | 40.99 Mn |
| Dec 31, 2025 | 1.68 Mn |
| Sep 30, 2025 | 24,086.70 Bn |
| Jun 30, 2025 | 48,078.50 Bn |
| Mar 31, 2025 | 21.51 Mn |
| Dec 31, 2024 | 1.54 Mn |
| Sep 30, 2024 | 16.38 Mn |
| Jun 30, 2024 | 15.02 Mn |
| Mar 31, 2024 | 18.66 Mn |
| Dec 31, 2023 | 10.29 Mn |
| Oct 31, 2023 | 12.74 Mn |
| Jul 31, 2023 | 7.53 Mn |
| Jan 31, 2023 | 8.61 Mn |
| Oct 31, 2022 | 6.37 Mn |
| Oct 31, 2021 | 14.21 Mn |
| Apr 30, 2021 | 5.05 Mn |
| Jan 31, 2021 | 3.00 Mn |
| Oct 31, 2020 | 3.69 Mn |
| Jul 31, 2020 | 2.13 Mn |